tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Albireo Pharma (ALBO), Precision BioSciences (DTIL) and Ayala Pharmaceuticals (AYLA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Albireo Pharma (ALBOResearch Report), Precision BioSciences (DTILResearch Report) and Ayala Pharmaceuticals (AYLAResearch Report) with bullish sentiments.

Albireo Pharma (ALBO)

In a report released today, Andreas Argyrides from Wedbush maintained a Buy rating on Albireo Pharma, with a price target of $61.00. The company’s shares closed last Monday at $24.93.

According to TipRanks.com, Argyrides is a 3-star analyst with an average return of 10.3% and a 48.3% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Global Blood Therapeutics, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Albireo Pharma is a Strong Buy with an average price target of $57.50, a 143.7% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $54.00 price target.

See the top stocks recommended by analysts >>

Precision BioSciences (DTIL)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Precision BioSciences today and set a price target of $20.00. The company’s shares closed last Monday at $2.06, close to its 52-week low of $1.11.

According to TipRanks.com, Trucchio ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -6.7% and a 42.9% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Arrowhead Pharmaceuticals, and Milestone Pharmaceuticals.

Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $9.00, which is a 354.5% upside from current levels. In a report issued on August 8, JonesTrading also maintained a Buy rating on the stock with a $8.00 price target.

Ayala Pharmaceuticals (AYLA)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ayala Pharmaceuticals, with a price target of $12.00. The company’s shares closed last Monday at $1.25, close to its 52-week low of $0.70.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -29.0% and a 24.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, MoonLake Immunotherapeutics, and Aquestive Therapeutics.

Ayala Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALBO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More